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Prevalence of Rare Genetic 
Variations and Their Implications  
in NGS-data Interpretation
Yangrae Cho1,2, Chul-Ho Lee3, Eun-Goo Jeong1, Min-Ho Kim1, Jong Hui Hong1, Younhee Ko3,4, 
Bomnun Lee1, Gilly Yun1, Byong Joon Kim1, Jongcheol Jung1, Jongsun Jung1 & Jin-Sung Lee3
Next-generation sequencing (NGS) technology has improved enough to discover mutations associated 
with genetic diseases. Our study evaluated the feasibility of targeted NGS as a primary screening tool to 
detect causal variants and subsequently predict genetic diseases. We performed parallel computations 
on 3.7-megabase-targeted regions to detect disease-causing mutations in 103 participants consisting of 
81 patients and 22 controls. Data analysis of the participants took about 6 hours using local databases 
and 200 nodes of a supercomputer. All variants in the selected genes led on average to 3.6 putative 
diseases for each patient while variants restricted to disease-causing genes identified the correct 
disease. Notably, only 12% of predicted causal variants were recorded as causal mutations in public 
databases: 88% had no or insufficient records. In this study, most genetic diseases were caused by rare 
mutations and public records were inadequate. Most rare variants, however, were not associated with 
genetic diseases. These data implied that novel, rare variants should not be ignored but interpreted 
in conjunction with additional clinical data. This step is needed so appropriate advice can be given to 
primary doctors and parents, thus fulfilling the purpose of this method as a primary screen for rare 
genetic diseases.
Timely diagnosis of genetic diseases could give newborns a chance to live healthy, independent lives as opposed 
to lives of disability and frequent or prolonged hospital visits. Tandem mass spectrometry, or MS/MS, is used in 
California to screen for selected genetic disorders of metabolism, endocrine disruptions, humoral diseases and 
cystic fibrosis1. This same method is used to screen for six metabolic diseases in the Republic of Korea (ROK) and 
is free to all newborns. In addition, most medical institutes, including public clinics and private hospitals, provide 
similar screening services for over 50 diseases detectable by MS/MS. Primary screening of genetic disorders by 
this method is fast and economical, but the false positive rate is over 90% according to a report by the President’s 
Council on Bioethics in the USA2. The trend is similar in the ROK, with false positive rates above 90% (T. Kim, 
personal communication).
Despite false positives, MS/MS is used to screen for neonatal metabolic diseases because early detection is 
critical for preventative treatment and preemptive management of devastating neonatal genetic diseases. Genetic 
screening is used as a secondary confirmatory test after a primary screening with MS/MS. Genetic testing was 
generally performed one gene at a time using Sanger sequencing. Recently, next-generation sequencing (NGS) 
was used to scan many genes at the same time2–8. Due to its high cost or labor intensity, this test was limited to 
patients with clinical indications or family history2.
With the advancement of NGS technology, the cost per base for determining the nucleotide sequence of many 
genes at the same time was dramatically reduced. The power of NGS technology made whole-genome sequencing 
(WGS) or whole-exome sequencing (WES) possible and showed promise for early screening of genetic disorders 
in newborns and for pediatric diagnostic medical care9–13. If NGS is to be used as a primary means for screening 
genetic disorders in newborns, however, several technical issues need to be addressed. They include noninvasive-
ness, reasonable turnaround time, affordable cost, and reasonable interpretation of variants. Dry Blood Spot (DBS) 
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has been used routinely to extract a sufficient amount of DNA for subsequent NGS use. Collecting DBS is mini-
mally invasive to newborns, extracts less than 75 µl of blood, and the sample is easy to store for future use2, 6, 14, 15. 
Turnaround time from DBS collection to NGS analysis can be as short as 5 days (equivalent to 105 hours) This 
is an acceptable interval for a rapid neonatal screening test2. The associated cost, however, would be too high for 
routine primary screening. The main expense is the prohibitive fixed cost of high-throughput NGS sequencing 
and subsequent data analysis, although technological innovation has reduced the cost per base.
Our goals in this study were to test a high-performance computing platform to analyze targeted NGS (TNGS) 
in silico; to assess the ability to discover variants with little public information but associated with specific genetic 
disorders; and to discuss issues regarding the interpretation of rare variants, with insufficient public records, in 
targeted genes associated with genetic disorders.
Results
Speed of Data Analysis. Target regions for intended sequencing were 3.7 Mb and included all positions in 
5,770 exons of 362 genes, plus 13,000 positions with biological importance. The entire process was performed as 
part of a validation to benchmark the results, optimize selection logic, and estimate computation time from the 
BAM file to the final results. When one node of a computer was used, it took about one hour to produce a recal-
ibrated BAM file and another four hours to create a file of candidate genes associated with rare genetic diseases. 
This file included annotated information on the frequency at which variants occurred in four different popula-
tions and the functional importance of sequence variations. It would take 58 days to analyze 103 samples if one 
node was used, but it took only 5 hours to complete the same analysis using 200 nodes of a server-class computer.
(Fig. 1, Table 1).
NGS Sequencing Statistics. We scanned the 3.7-Mb regions and discovered that all variants in the regions 
were sequenced at an average depth of 161× reads, but focused our analysis on 307 of the 362 genes in 1.38 Mb. 
We excluded 55 of the 362 genes because they were not associated with rare genetic diseases, but with other 
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Figure 1. Work flow for generation of a binary alignment matrix (BAM). These files were used in subsequent 
genotyping and variant discovery with four separate variant calling methods.
Number of 
samples Sample Size
Computation time
FASTQ to BAM BAM to VCF Total (Hour)
1 1.0GB 0:45 2:30 3:15
1 1.5GB 1:05 3:30 4:35
1 2.8GB 2:03 6:50 8:53
103 165GB (1.5 GB ea.) 1:05 3:30 5:00*
Table 1. Summary of specifications for the computation time for 103 DNA samples versus one DNA sample. 
OS: CentOS6.5, CPU: Intel Xeon 2Socket E5520 2.3 GHz 4Core × 200Node (total = 1,600 Cores), Disk Drive: 
MAHA distributed parallel file system for diagnosis (MAHA-FsDx: 1.4 PetaByte). *The actual time required for 
the analysis of 103 samples on 200 nodes of a MAHA-FsDx, parallel computer was 5 hours, instead of 4 hours 
35 minutes.
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common features such as blood and HLA types (Supplementary Table S1). Sequence depth averaged 128× for 
the 307 genes in subsequent data interpretations (Table 2, Supplementary Table S2). Capture performance data 
indicated that 96% of the targeted bases were covered at a minimum depth of 20× reads (Fig. 2). The remaining 
4% of the regions were either not sequenced or were inadequately aligned. We did not pursue the reasons for the 
missing sequences. NGS sequencing can be affected by various factors such as poor capturing due to high G/C 
content or repetitive sequences. Read depth for 79% of the targeted regions exceeded a minimum coverage depth 
of 61× (Fig. 2). Sequence variants initially were determined for all positions regardless of read depths. An average 
of 11,463 (s.d. 199) variants were detected among the 3.7-Mb positions included in the panel, and 1,186 (s.d. 
57.2) of the 11, 463 variants occurred within the 307 genes. Because several authors indicated a minimum read 
depth coverage of 20× for accurate genotyping of a base16, 17, we used 20× in our downstream analysis to discover 
sequence variants. Because sequence coverage exceeded 30× for 93% of all samples we also used 30× with an 
expectation that it would minimize calling errors. There were no differences, however, between the 20× and 30× 
sets in the final sets of variants.
Patient Selection. The study group was comprised of 81 patients with disease-causing mutations, 10 
patients with carrier mutations, and 12 negative controls. For the 81 patients, diseases were diagnosed based on 
symptoms and other test results. Causal mutations were confirmed by Sanger sequencing prior to or during this 
study. Information on the causal mutations was not provided to the analysis team initially. This allowed the team 
to objectively assess the ability of NGS to discover causal variants.
Optimization of Discovery Process/Orientation to Data. Results for base calls from the NGS work-
flow were compared with the results of Sanger sequencing in other studies2, 3, 8, 18, 19. We randomly selected 25 
of the 103 patients during the initial discovery stage of variants in silico (Table 3, Supplementary Table S3) to 
optimize our informatics approach for discovering clinically important variants. There were 23 patients with 
predefined causative mutations for genetic disorders and two patients with variants but no causative mutations. 
This information was not disclosed to the analysis team, who suspected that all subject patients had causative 
mutations. Filtering the causal genetic variants from >99% of benign variants was based on information about 
the functional importance predicted by PolyPhen (ver. 2.2.2) and their frequency among healthy populations for 
each variant. Each individual had ~2,000 variants within the 307 genes and PolyPhen predicted an average of 
75 variants with damaging effects. Screening by minor allele frequencies below 4% among general populations 
left on average 8.6 candidates as causal variants. Through manual curation, we identified 29 variants in 23 sam-
ples and missed 3 variants in 2 samples. The three variants were discovered initially by targeted NGS (TNGS), 
Captured 
regions
307 
genes
211 
genes 65 genes
Sum of reads on target regions 575 Mb 138 Mb 109 Mb 43 Mb
On target rates1 30% 7.20% 5.20% 2.20%
Length of target regions 3.7 Mb 1.3 Mb 0.9 Mb 0.35 Mb
Mean read depth2 161× 128× 120× 127×
Number of variants NA 1186 762 271
Number of rare variants with probable deleterious effects NA 8.6 6.2 3.4
Number of disease candidates NA 3.6 2.7 1.8
Table 2. Statistics for sequence-read coverages and rare variants leading to the causal variants for rare genetic 
diseases in each patient. 1[(Sum of reads on target regions)/(sum of all reads, 2.1 Gigabytes)] × 100. 2(Sum of 
reads on target regions)/(length of target regions).
Figure 2. Read depth distribution for the target calculated by the formula: sum of read numbers in each bracket 
divided by the number of total positions. Read depth distribution for the target was similar for both the 65 and 
307 target genes. The blue line almost overlapped the orange line.
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but inadvertently excluded during a further selection procedure because their frequency was above 5% among 
healthy people. These were polymorphic nucleotide sequences and served as negative controls. In conclusion, all 
predefined variants were rediscovered using TNGS, but three variants were excluded during the final selection 
stage because they were unlikely causal mutations of genetic diseases based on their high frequencies among 
healthy populations.
The analysis algorithm was designed to discover mutations in genes associated with clinical symptoms. Only 
5 of 25 (20%) patients showed causal mutations previously associated with genetic disorders that also had infor-
mation deposited in public databases (Table 3). The other 20 (80%) patients had rare variants with little or no 
information available. These mutation types included 8 SNVs in 6 (24%) patients, nonsense mutations in 5 (20%) 
patients, short indels in 3 (12%) patients, and gene deletion or duplication in 4 (16%) patients. These results were 
a surprise to the analysis team who expected most of the causal mutations to be in public databases, as reported 
in other cases20–22. In addition, compound heterozygosity was the cause of genetic disorders in 7 of 25 (30%) 
patients. This information was included in the identification of all disorders in our subsequent analysis of the 103 
samples.
Patient # Gene Variants Variant type
Variant 
call Heredity1
Known single nucleotide variant (SNV)
37 FGFR3 (Gly382Arg (c.1138G > A, het) rs28931614 Yes AD
71 PAH p.Arg243Gln (c.728G > A) rs62508588 Yes AR
71 PAH c.442-1G > A rs62514907 Yes AR
83 RB1 c.1215 + 1G > A rs587776783 Yes AD
89 SOS1 p.Arg552Gly(c.1654A > G) rs137852814 Yes AD
102 WT1 p.Arg462Trp(c.1384 C > T, het) rs121907900 Yes AD
Introduction of stop codon (nonsense mutation)
1 ABCA12 p.Arg2482*(c.7444 C > T) stop Yes AR
1 ABCA12 p.Arg1950*(c.5848 C > T) stop Yes AR
46 GCH1 p.Glu242*(c.724 G > , het) stop Yes AD
56 JAG1 p.Tyr434* (c.1302 C > A, het) stop Yes AD
62 NF1 p.Gln554*(c.1660C > T) stop Yes AD
84 RB1 p.Arg272* (c.814 A > T, het) stop Yes AD
Insertion and deletion (indel)
34 FBN1 c.1698_1712del15(exon13, het) ins Yes AD
55 JAG1 c.1 720 + 1dupG(intron13, het) del Yes AD
100 VPS33B c.740_741delAT(exon10,het) del Yes AR
100 VPS33B c.403 + 2 T > A(intron6,het) ins Yes AR
Single nucleotide variant (SNV) without public records
10 ARSA p.Cys493Ser (c.1478G > C,het) SNV Yes AR
10 ARSA p.Asp411Gly (c.1232A > G,het) SNV Yes AR
24 COL1A2 c.595-1G > C SNV Yes AD
26 COMP p.Asp376His (c.1126 G > C,het) SNV Yes AD
54 IVD p.Ala29Thr (c.85G > A,het) SNV Yes AR
77 PKHD1 p.Leu2665Pro(c.7994T > C) SNV Yes AR
77 PKHD1 p.Val836Ala(c.2333G > T) SNV Yes AR
97 TSC2 p.Gly1204Arg(c.3610G > C, het) SNV Yes AD
Variant with high frequency among healthy people2
39 GALC p.Ile562Thr(c.1685T > C, homo) SNV No x 27%
47 GJB2 p.Gly114Glu SNV No x 5%
47 GJB2 p.Val27Ile SNV No x 8%
Big deletion
7 PRODH 1 copy del gene del Yes AR
7 PRODH p.Leu441Pro SNV Yes AR
15 BTK del. Exon6~10 (both copies) partial del Yes 2 copies
29 DMD exon2~exon7 duplication partial dup Yes AD
60 MECP2 MECP2 duplication gene dup Yes AD
Table 3. Call for disorders based on nucleotide sequence variations detected by next-generation sequencing 
1Heredity = basis for calling disorders; AD = autosomal dominant inheritance; AR = autosomal recessive 
inheritance, x = No call. Bold indicates a patient with a disorder resulting from composite heterozygotes, 
phasing issue not resolved but regarded as trans; 2Disease call was unsuccessful due to a high frequency of alleles 
among healthy populations.
www.nature.com/scientificreports/
5Scientific RePoRTS | 7: 9810  | DOI:10.1038/s41598-017-09247-5
Analysis of Results for 103 Participants. We used the same set of algorithms in a blind retrospective 
validation of variants for all 103 participants. There were 108 predefined causal mutations and 13 negative con-
trols among the 103 participants: 81 patients, 10 carriers, and 12 healthy people. Of the 121 variants in 65 genes, 
13 were negative controls, 10 were carrier mutations, and 98 were associated with genetic diseases (Table 4). Of 
the 81 patients, 57 (70%) had SNV mutations with a dominant disease inheritance and 13 (16%) had mutations 
for a recessive type of disease inheritance. For patients with two mutations in a single gene, we did not know 
their phase but hypothesized trans and interpreted it as a compound heterozgote. We detected 115 of the 121 
variants (analytical sensitivity 95%, analytical specificity 100%) by analyzing TNGS. We either failed to detect, 
or excluded, six causal mutations during the selection step. In two patients, sequence reads for the IKBKG gene 
were too low to detect variants. We checked the BAM file and the sequence alignment file to confirm the absence 
of sequence reads for this gene. The expansion of trinucleotide repeats in PARM was not detected in one patient, 
though sequence depth was over 100×. In three patients, variants were detected by TNGS but excluded during 
final selection of disease-causing mutations because they were in the intron regions and 5 and 14 nucleotides away 
from splicing sites. We decided to exclude them because there was insufficient information to properly interpret 
the genetic effects of these mutations. We concluded that we could reliably detect most variants, SNVs and CNVs 
using TNGS with their current capturing probes, but could not detect the expansion of three nucleotide repeats 
nor interpret the importance of variants within introns.
When all 307 genes were considered, each patient had an average of 8.6 (s.d. 0.9) variants that were function-
ally deleterious according to PolyPhen analysis. These variants occurred at low frequencies (<4%) among healthy 
people in the 1000 Genome Project (phase 3)23, 24 and 4 other Korean populations (JJ, unpublished data). We 
selected 16 variant positions in 4 patients and resequenced them using the Sanger method. Twelve positions were 
successfully amplified by PCR and produced sequence information confirming the TNGS results (Supplementary 
Fig. S1). Based on the selected variants, we predicted all possible disorders in each patient. Literal interpretation 
of the 8.6 variants resulted in an average of 3.8 putative diseases per patient (Table 2). When we considered a 
subset of the 65 genes (Supplementary Table S2) responsible for the 57 diseases in 81 patients included in this 
study, there were on average 1.8 possible genetic disorders in each patient. For the 65 selected genes, 96% of the 
targeted bases were covered at a minimum depth of 20× reads (Fig. 2). When we reduced the number of genes 
to those associated with a specific disease, only one or two variants were associated with the selected disease for 
each patient.
Some patients had known mutations that caused the same amino acid changes as in established pathogenic 
variants. These mutations were also prevalent in patients affected with dominantly inherited diseases. For these 
patients, diagnostic evidence was strong for calling a specific genetic disorder, as described in the ACMG guide-
lines for the interpretation of sequence variants25. For example, a patient with the dominantly inherited SNV 
Gly382Arg (c.1138 G > A, rs28932614) in FGFR3 had the genetic disorder, hypochondroplasia (OMIM 146000). 
Among 81 patients, only 10 (12%) had mutations known to be associated with genetic disorders (Table 4). Two 
patients had a recessively inherited causal mutation plus an additional mutation in the same gene. Information 
on both variants was used to describe the disease as a compound heterozygote. The other 71 (88%) patients 
had rare mutations and no information was available in OMIM (https://www.ncbi.nlm.nih.gov/omim), ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar), or PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) databases. Four 
of 71 patients each had both copies of a gene deleted, simplifying an association between genes and responsi-
ble diseases with strong evidence based on the guidelines25. Deletion of both copies through exons 6 to 10 of 
the ALDH4A1 gene in patient 15 likely caused the genetic disorder, hyperprolinemia (OMIM 942510). Disease 
association was also relatively straightforward when the variants introduced a premature stop codon either by 
Type of variant
# of 
samples
# of 
variants Relevant genes Detection
SNV/Trinucleotide expansion 6 6 CYP21A21, IKBKG2 PAH1, PARMS3, VPS33B1 Failure
Single Nucleotide Variation (SNV, 
AD, AR-homo) 54 57 Success
Compound heterozygote 13½ 4 27 ABCA12, ACADM, AGL, PRODH, ARSA, ATP7B, GALC, GBA, HEXA, MCCC1, PAH, PKHD1, VPS33B Success
Copy Number variation (CNV) 7½4 8 PRODH, BTK, DMD, MECP2, PMP22, STS Success
Carrier (het, inheritance type = AR) 10 10 ATP7B, BTK, GALT, GBA, HBB, IVD, LMNA, MCCC2, PRODH, SLC22A5 Success
Negative control 12 13 ABCC8, ACADS, ALPL, CFTR, CYP21A2, GALC, GALT, GJB2, GJB2, NF1, OTC, PMP22, VHL Success
Total number 103 121
Predefined variant 121
Correct answer 115
Incorrect answer 22 6
Analytical sensitivity 95% 115/121
Table 4. Summary of variant types in 103 participants. 1Variants in introns were detected by TNGS, but 
excluded from disease calling due to ambiguity of their biological roles. 2Read depth was zero for IKBKG. 
3Repeat expansion from 20 to 25 was not detected. 4Patient number seven was a heterozygote with two types of 
variants.
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SNVs or short indels. This occurred even though their association with genetic diseases was not established in 
public databases. Of the 81 patients, 12 had nonsense mutations by SNVs and 20 had indel mutations. Missense 
mutations occurred in 34 patients and their impact required cautious interpretation. Another group of 14 patients 
had mutations at two locations in one gene. For example, one patient was a suspected compound heterozygote 
for PAH (p.Arg243Gln (c.728 G > A rs62508588), (c.442–1 G > A, rs62514907), OMIM 261600), indicative of 
phenylketonuria disease. Although both mutations were associated with genetic disorders, solving the phase 
issue of the mutations was technically required to confirm that both copies of the gene were affected. Our deci-
sions were made in this study based on the hypothesis that the mutations were associated with certain diseases. 
We confirmed our decisions on 14 diseases based on compound heterozygosity when the patients’ information 
was available. In summary, we were able to identify the causal mutations and correctly diagnose 75 of 81 (92.5%) 
patients when disease information was available.
Discussion
The panel used in this study was designed to screen mutations in 307 genes associated with 159 genetic dis-
eases. The list of diseases included 140 rare genetic disorders recommended for prenatal screening by the Health 
Ministry, ROK, and ~60 neonatal metabolic diseases commonly screened in many hospitals in the ROK. We 
sequenced 96% of the 3.7-Mb target regions with over 20× coverage in this study and reliably found SNVs, 
short indels, and CNVs. The sensitivity for finding 121 predefined positions was 95%. Limitations were in failed 
sequencing, detecting the expansion of trinucleotide repeats, and interpretation of variations within intronic 
regions (Table 4). We conducted numerous experiments to validate NGS results and Sanger sequencing consist-
ently supported the accuracy of base calls for SNVs and small indels at exon regions (Supplementary Fig. S1; JJ, 
in preparation). Sequence coverage patterns were consistent among all 103 samples with only 4% of the targeted 
regions covered by less than 20×. We focused our analyses on the 96% of well-sequence regions. This approach 
allowed us to multiplex 103 samples and run them in two lanes of HiSeq. 2000.
Among all variants suspected as causal mutations for diverse genetic diseases, only 12% were in public records. 
There were no or insufficient public records for the other 88%. Our results suggested that screening of previously 
known causal mutations alone was insufficient and novel variants had to be considered to comprehensively iden-
tify causal mutations and reduce false negative results. If the analysis team had ignored the variants not present 
in public records, the team would have missed diagnosing over 80% of the diseases. We also had to consider that 
genetic diseases might result from mutations outside of the exome26. There are sporadic reports on the roles of 
introns in regulatory functions and in proper gene splicing27. Informal polling among geneticists suggested that 
exome-based discovery of causative mutations identifies less than 50% of cases28. Thus it may be necessary to 
sequence whole genic regions, including complete introns and regulatory regions. The cost of TNGS is now low 
enough that adding introns would not substantially increase the price. It would still be challenging, however, to 
understand the effect of mutations in introns; we failed to predict their deleterious effects in three cases even after 
detecting their presence.
We primarily evaluated the accuracy of TNGS in detecting variants and in discovering disease-causing vari-
ants among them without prior information on causal mutations. We predicted the candidates of causal variants 
for 307 genes without knowing the name of the disease. We then made predictions knowing the disease names 
associated with each sample. When the disease names were not known, we attained multiple causative variants 
for several putative diseases with similar weight in each patient. A large amount of sequence information was 
available for several populations in the world23, 24, 29, 30. Although the information on allele frequencies of genetic 
variants was insufficient to distinguish extremely rare causal mutations from low-frequency polymorphisms, it 
was a very effective tool to reduce the number of candidate variants (see below).
PolyPhen alone predicted more than one disease, including one that was patient specific. On average 75 var-
iants were predicted by PolyPhen as having damaging effects. The sensitivity was close to 95%, but specificity 
was low due to the over-prediction of missense variants as pathogenic mutations. Our results were consistent 
with knowledge that algorithms either predict missense variants or over-predict as known disease variants with 
65–80% accuracy31, 32. We could have improved the program after the initial tests, but it seemed apparent that 
the pathogenic variants detected by PolyPhen were only candidates of causal variants and not truly pathogenic 
variants. It is of note that the list of candidate variants was reduced from 75 to 8.6 on average when we removed 
variants with allele frequencies over 4% among healthy populations. The list of candidate variants associated 
with the disease in each patient became apparent when we incorporated the disease names into the analysis. The 
penetration rate of causal variants can vary depending on genetic background, regardless of their extremely low 
frequency33. Thus, additional information is needed to unequivocally establish a cause-and-effect relationship 
between a mutation and a disease, This information could include: 1) sequence data for the unaffected parents 
and the affected child, 2) the same mutations in an affected sibling and the unmutated genes of a healthy sibling, 
and 3) at least two cases of independent mutations in one gene34. We have been working on several cases to estab-
lish a cause-and-effect relationship between mutations and diseases (JSL, in preparation).
Next-generation sequencing is powerful enough to be used for primary screening of rare genetic disorders. 
There have been several attempts to use NGS as the initial screening method in the Republic of Korea. Health 
Insurance Review and Assessment Services in the ROK decided to cover the diagnostic services and reimburse 
the associated expense from March 1, 2017. However, three major issues must be addressed to make these services 
sustainable: reasonable turnaround time, affordable cost, and proper interpretation of variants17.
Turnaround time and cost are two intertwined issues. NGS delivers large amounts of sequence data, but has been 
too expensive to routinely apply to neonatal screening of genetic disorders. The read number and cost of sequencing 
runs are fixed regardless of the sample numbers. The technology would be cost effective if TNGS was combined 
with the parallel processing of sequencing reactions. For example, if 48 samples were run together, TNGS of a 1-Mb 
region with a 1-Gb output would probably cover ~500× reads with a total sequencing cost of less than $400. The 
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demand for testing individual genetic diseases is likely too low to take advantage of the parallel processing of multiple 
samples. Individual diseases are rare, usually less than 1 in 10,00035. The expected incidence of Wilson’s disease, for 
example, was 1 in 36,000 newborns, or about 10 patients each year in the ROK36. Over 5,000 genetic diseases caused 
by SNVs, short indels, or CNVs are recorded in the OMIM database (https://www.ncbi.nlm.nih.gov/omim)37. Test 
panels examining numerous genes and CNVs affecting over 100 diseases instead of just a few, would be clinically val-
uable and economically viable. Parallel computation and interpretation of data appeared to solve another cost issue 
for many patients that arose from the analysis of NGS data. It took about 5 hours instead of 58 days to identify rare 
variants in 103 samples when 200 nodes of a supercomputer were used for the analysis (Table 1). A company with 
the computation capacity could serve as a Biological Computation Center to hospitals with small-scale computation 
facilities. Computation time would not be a bottleneck for NGS analysis used in disease screening even if numerous 
sequences were multiplexed. Any panel design to detect both SNVs and CNVs would further expand the coverage of 
genetic diseases. This could increase demand for the panel, shorten turnaround time, and lower cost.
When many genes are examined in a single test, more rare variants can be screened and considered for their 
possible association to disease. When screening variants in patients with accurate phenotypic characterizations, 
few candidates among the over 5,000 diseases in the OMIM database would help identify the narrow set of candi-
date genes for a disease. An expanded range of candidate genes might increase the odds of identifying the causal 
variants. If TNGS were used to screen for neonatal diseases before symptoms appeared, all variants in all genes 
could be considered as candidates of disease-causing mutations. If rare variants with insufficient public records 
were excluded from the screening, over 80% of potential diseases would not be reported, producing false negative 
results. It would be ethically and scientifically inappropriate not to report all rare variants. Conversely, reporting 
all variants would lead primary doctors and parents into a dilemma, if not panic. They would be faced with an 
avalanche of data without knowing the possible implications. In this study, 8.6 variants were associated with 3.4 
diseases in each person when 307 genes were analyzed. About 88% of the variants were uncommon mutations 
among healthy people and not causing genetic diseases. Therefore, appropriate notice or instruction must be 
given so physicians can review family histories and check patients for symptoms of known genetic diseases. TNGS 
could provide nationwide screening for genetic diseases caused by SNVs and CNVs in the near future. A collec-
tive scientific effort is needed to develop TNGS as a primary screen for rare genetic diseases.
Materials and Methods
Target Genes for NGS. We developed clinical test panels to screen for rare mutations associated with 159 
genetic diseases (Supplementary Table S1). A targeted gene enrichment method was used to construct librar-
ies for subsequent determination of sequences using a next-generation sequencing (NGS) method with HiSeq 
(Illumina, San Diego, California). The probe set was designed to capture 3.7 megabases (Mb) covering the exonic 
regions and 25 nucleotides at the flanking intronic areas for 362 targeted genes plus 13,000 biologically impor-
tant locations. Probe-library hybridization followed by capturing target genes was performed according to the 
manufacturer’s instructions. A list of the 362 genes examined in this study is shown in Supplementary Table S1.
Sample Preparation. We used DNA samples from 103 participants, including 81 patients with clinical symp-
toms previously monitored and diagnosed at Yonsei Severance General Hospital, ROK. The study was approved by 
the institutional review board and the ethics committee of the hospital. All methods were performed in accordance 
with the relevant guidelines and regulations as described below. Written informed consent for genetic testing, or 
a waver, was obtained from each participant or family. All samples were randomly numbered and processed in 
accordance with hospital guidelines, from library construction to subsequent sequencing and analysis. Samples from 
patients were collected over a 10-year period from 2006 to 2015. DNA was extracted from a 200-µl blood sample 
with the QIAcube System and QIAamp DNA Blood Mini Extraction Kit (Qiagen, Valencia, California) and stored in 
10 mM Tris buffer solution at −20 °C. DNA extraction, library construction and HiSeq. 2000 (Illumina, San Diego, 
California) running were performed at the Clinical Genetics Laboratory, Yeonsei University (Seoul, ROK).
Library Preparation and Sequencing. DNA quality was evaluated when it was quantitated with 4200 
TapeStation (Agilent, UK). A sequencing library was constructed with 500 ng of acceptable-quality genomic DNA, 
as described below. We fragmented the DNA into 150- to 200-base-pair (bp) segments with a NEBNext dsDNA 
Fragmentase® (New England Biolabs, UK), according to the manufacture’s protocol. The enzyme-fragmented 
DNA was subsequently used to construct a library according to the protocol provided by Cellemix (Seoul, ROK). 
Briefly, the library was constructed by repairing blunt ends, adenylating the 3′ ends, and ligating the adapters. 
The adapter-ligated library was amplified using six cycles of polymerase chain reaction. The concentration and 
clone-size of each library were examined at this stage. For the enrichment of the library, we used a custom probe 
set designed by Syntekabio, Inc. (Daejeon, ROK) and synthesized by Cellemix (Seoul, ROK).
Following the capturing procedure, the samples were tagged with index primers using 24 cycles of post-capture 
amplification. The concentration and clone size of each amplified library were then examined. A total of 96 sam-
ples with different index tags were pooled and sequencing performed on a HiSeq. 2000. Each sample generated 
150-bp, paired-end sequencing reads. To minimize lane-to-lane variation, an equal amount of indexed library was 
combined before the sequence run.
Analysis of Sequence and Detection of Variants. We analyzed the NGS data using a series of algo-
rithms in a predetermined order (Fig. 1). Raw image files were converted to base calls by real-time analysis on 
HiSeq, using the default settings recommended by the manufacturer (Illumina, San Diego, CA). The output base 
call files (*.bcl) generated by the real-time analysis were converted to FASTQ files with consensus assessment of 
sequence and variation (CASAVA pipeline, version 1.8, Illumina). CASAVA also demultiplexed the data to obtain 
FASTQ files for individual samples. The FASTQ files were sent to Syntekabio, Inc. for sequence alignment and 
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further analysis (Fig. 1). A Burrows-Wheeler aligner (BWA-MEM; version 0.7.1038) was used with default param-
eters to align the sequence reads to the human reference genome sequence GRCh37. Alignments in the sequence 
alignment/map (SAM) format were converted to binary alignment map (BAM) files implemented in SAM tools 
(SAM tools version 0.1.1039). Picard tool (version 1.119; http://picard.sourceforge.net) was used to remove dupli-
cate reads and to sort sequence reads in the order of their start position. BAM files were realigned to the reference 
sequences Ch37d.5.fa with GATK Realigner Target Creator and local alignment was fine-tuned with GATK Indel 
Realigner. The GATK base-quality recalibration tool, GATK Base Recalibrator, was used to recalibrate base qual-
ity scores. Subsequently, a fine-tuned BAM file generated by GATK PrintReads was used for variant calling. For 
the above described analyses, we used algorithms imbedded in GATK software tools (version 3.3.0; http://www.
broadinstitute.org)40. CNVnator41 and Contra42 were used to detect copy number variations.
Coverage Analysis. Before discovering single nucleotide variants (SNVs), indels, and copy number variants 
(CNVs), we analyzed coverage in the targeted exons and estimated target enrichment. To compute minimum, 
maximum, and average coverage of each exon, BAM files containing coverage data were first converted to pileup 
with SAM tools. We recalibrated the BAM file as described above. Subsequently, Picard CalculateHsMetrics tools 
(Broad Institute, https://broadinstitute.github.io/picard/) was used to calculate on-target rates. The program gen-
erated a metrics file containing “on-target bases” and “mean coverage (depth)” on the bed file. On-target rates 
were calculated by the equation, on-target bases/total bases.
Analysis of Variants. The analysis team investigated whether the variations in question were previously 
reported by searching local databases reflecting the Online Mendelian Inheritance in Man (OMIM, NCBI, http://
omom.org, 09–01–2016) and ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/)43. For previously published vari-
ants, information on OMIM, ClinVar, and PubMed (US National Library of Medicine, Bethesda, Maryland) was 
consulted to determine the functional significance of the identified variants and select the candidates of causative 
variations for diseases. We evaluated the functional importance of novel variants using the software PolyPhen 
(ver. 2.2.2)44, 45. For each variant, regardless of its functional importance, we calculated its frequency at each 
position among the population to evaluate the prevalence of the identified variants in human populations. We 
used the following databases: the 1000 Genomes Project (phase 3)23, 24, the dbSNP database (build version 144, 
NCBI, Bethesda, Maryland), 2000 people in the International Cancer Genome Consortium29, 30, the 1000 Korean 
Genome, and the 500 healthy babies (JJ, unpublished data) database. Large deletions that may have resulted from 
hemizygous or composite heterozygous mutations were not distinguished in this study. We built and used local 
databases for the OMIM, ClinVar, and PolyPhen results, and allele frequencies in different populations when 
classifying the functional importance of each variant.
Verification of Mutations by Sanger Sequencing. All positions associated with genetic diseases were 
sequence-verified by the Sanger method. In addition to positions showing causal mutations, we also determined 
the sequences of other positions in four samples with rare genetic variations. For Sanger sequence verification, we 
performed PCR amplification using 10ng of genomic DNA. Primers for the PCR reactions were designed using 
NCBI/Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The size of amplified PCR products was 
designed to be in the range of 414 to 681 bp (Supplementary Table S4). For PCR amplification of the fragments, 
H-Star Taq DNA Polymerase (BIOFACT Co. Ltd, Daejeon, Korea) was used. PCR products were purified with a 
Gel & PCR Purification Kit (BIOFACT Co. Ltd, Daejeon, Korea) and used as a template for Sanger sequencing. 
Chromatograms were manually inspected to confirm the sequence accuracy of each file. The information on chro-
mosome positions of variants, sequence of each primer, and amplicon sizes is provided in Supplementary Table S4.
Analytical Validation. Analytical sensitivity and specificity were respectively calculated by the formulas, 
TP/(TP + FN) and TN/(TN + FP), where TP, TN, FP, and FN were respectively true positive, true negative, false 
positive, and false negative. Sequence variants identified through the analysis of NGS data were compared to 
the predefined variants determined by Sanger sequencing. We included 121 positions in the calculation of true 
positive, true negative, false positive, and false negative. True positives were identically sequenced as positive at 
the 121 positions by both the Sanger and NGS methods. True negatives were the 120 positions for each patient 
and included all 121 sequenced positions except for a causative variant; they were negative by both the Sanger 
and NGS methods. False positives were any of the 121 positions with the wrong sequence and were negative by 
the Sanger method and positive by NGS. False negatives were wrong sequences for the 121 positions and were 
positive by the Sanger method and negative by NGS.
Data Availability. All data analysed during this study are included in this published article and its 
Supplementary Information files. The raw NGS datasets generated during the current study are not publicly avail-
able due to restrictive hospital policies but are available from the corresponding author on reasonable request.
References
 1. Feuchtbaum, L., Carter, J., Dowray, S., Currier, R. J. & Lorey, F. Birth prevalence of disorders detectable through newborn screening 
by race/ethnicity. Genetics in medicine: official journal of the American College of Medical Genetics 14, 937–945, doi:10.1038/
gim.2012.76 (2012).
 2. Bhattacharjee, A. et al. Development of DNA confirmatory and high-risk diagnostic testing for newborns using targeted next-
generation DNA sequencing. Genetics in medicine: official journal of the American College of Medical Genetics 17, 337–347, 
doi:10.1038/gim.2014.117 (2015).
 3. Al-Mousa, H. et al. Unbiased targeted next-generation sequencing molecular approach for primary immunodeficiency diseases. The 
Journal of allergy and clinical immunology 137, 1780–1787, doi:10.1016/j.jaci.2015.12.1310 (2016).
 4. Dong, Y. et al. Targeted next-generation sequencing identification of mutations in patients with disorders of sex development. BMC 
medical genetics 17, 23, doi:10.1186/s12881-016-0286-2 (2016).
www.nature.com/scientificreports/
9Scientific RePoRTS | 7: 9810  | DOI:10.1038/s41598-017-09247-5
 5. Lee, H. et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. Jama 312, 1880–1887, doi:10.1001/
jama.2014.14604 (2014).
 6. Lefterova, M. I. et al. Next-Generation Molecular Testing of Newborn Dried Blood Spots for Cystic Fibrosis. The Journal of molecular 
diagnostics: JMD 18, 267–282, doi:10.1016/j.jmoldx.2015.11.005 (2016).
 7. Stoddard, J. L., Niemela, J. E., Fleisher, T. A. & Rosenzweig, S. D. Targeted NGS: A Cost-Effective Approach to Molecular Diagnosis 
of PIDs. Frontiers in immunology 5, 531, doi:10.3389/fimmu.2014.00531 (2014).
 8. Vandrovcova, J. et al. The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia. Genetics in 
medicine: official journal of the American College of Medical Genetics 15, 948–957, doi:10.1038/gim.2013.55 (2013).
 9. de Ligt, J. et al. Diagnostic exome sequencing in persons with severe intellectual disability. The New England journal of medicine 367, 
1921–1929, doi:10.1056/NEJMoa1206524 (2012).
 10. Kaiser, J. G. Researchers to explore promise, risks of sequencing newborns’ DNA. Science 341, 1163, doi:10.1126/science.341.6151.1163 
(2013).
 11. Landau, Y. E., Lichter-Konecki, U. & Levy, H. L. Genomics in newborn screening. The Journal of pediatrics 164, 14–19, doi:10.1016/j.
jpeds.2013.07.028 (2014).
 12. Saunders, C. J. et al. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. Science 
translational medicine 4, 154ra135, doi:10.1126/scitranslmed.3004041 (2012).
 13. Yang, Y. et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. The New England journal of medicine 369, 
1502–1511, doi:10.1056/NEJMoa1306555 (2013).
 14. Hughes, E. E. et al. Clinical Sensitivity of Cystic Fibrosis Mutation Panels in a Diverse Population. Human mutation 37, 201–208, 
doi:10.1002/humu.22927 (2016).
 15. Poulsen, J. B. et al. High-Quality Exome Sequencing of Whole-Genome Amplified Neonatal Dried Blood Spot DNA. PloS one 11, 
e0153253, doi:10.1371/journal.pone.0153253 (2016).
 16. Luzon-Toro, B. et al. Next-generation-based targeted sequencing as an efficient tool for the study of the genetic background in 
Hirschsprung patients. BMC medical genetics 16, 89, doi:10.1186/s12881-015-0235-5 (2015).
 17. Yohe, S. et al. Clinical validation of targeted next-generation sequencing for inherited disorders. Archives of pathology & laboratory 
medicine 139, 204–210, doi:10.5858/arpa.2013-0625-OA (2015).
 18. Singh, R. R. et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. The 
Journal of molecular diagnostics: JMD 15, 607–622, doi:10.1016/j.jmoldx.2013.05.003 (2013).
 19. Simakova, T. et al. Identification of a novel, CF-causing compound genotype (p.S1159P and p.Y569H) using an NGS-based assay: 
Novel CF-causing compound p.S1159P and p.Y569H genotype. Gene 575, 567–569, doi:10.1016/j.gene.2015.09.040 (2016).
 20. Kim, B. G. et al. Limitations of hearing screening in newborns with PDS mutations. International journal of pediatric 
otorhinolaryngology 77, 833–837, doi:10.1016/j.ijporl.2013.02.023 (2013).
 21. Lee, B. H. et al. High prevalence of neonatal presentation in Korean patients with citrullinemia type 1, and their shared mutations. 
Molecular genetics and metabolism 108, 18–24, doi:10.1016/j.ymgme.2012.11.011 (2013).
 22. Woo, H. I. et al. Mutation spectrum of the ASS1 gene in Korean patients with citrullinemia type I. Clinical biochemistry 46, 209–213, 
doi:10.1016/j.clinbiochem.2012.10.008 (2013).
 23. Genomes Project, C. et al. A map of human genome variation from population-scale sequencing. Nature 467, 1061–1073, 
doi:10.1038/nature09534 (2010).
 24. Genomes Project, C. et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56–65, doi:10.1038/
nature11632 (2012).
 25. Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the 
American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in medicine: official 
journal of the American College of Medical Genetics 17, 405–424, doi:10.1038/gim.2015.30 (2015).
 26. Cartault, F. et al. Mutation in a primate-conserved retrotransposon reveals a noncoding RNA as a mediator of infantile 
encephalopathy. Proceedings of the National Academy of Sciences of the United States of America 109, 4980–4985, doi:10.1073/
pnas.1111596109 (2012).
 27. Guil, S. & Esteller, M. Cis-acting noncoding RNAs: friends and foes. Nature structural & molecular biology 19, 1068–1075, 
doi:10.1038/nsmb.2428 (2012).
 28. Lyon, G. J. & Wang, K. Identifying disease mutations in genomic medicine settings: current challenges and how to accelerate 
progress. Genome medicine 4, 58, doi:10.1186/gm359 (2012).
 29. International Cancer Genome, C. et al. International network of cancer genome projects. Nature 464, 993–998, doi:10.1038/
nature08987 (2010).
 30. Zhang, J. et al. International Cancer Genome Consortium Data Portal–a one-stop shop for cancer genomics data. Database: the 
journal of biological databases and curation 2011, bar026, doi:10.1093/database/bar026 (2011).
 31. Choi, Y., Sims, G. E., Murphy, S., Miller, J. R. & Chan, A. P. Predicting the functional effect of amino acid substitutions and indels. 
PloS one 7, e46688, doi:10.1371/journal.pone.0046688 (2012).
 32. Thusberg, J., Olatubosun, A. & Vihinen, M. Performance of mutation pathogenicity prediction methods on missense variants. 
Human mutation 32, 358–368, doi:10.1002/humu.21445 (2011).
 33. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291, doi:10.1038/nature19057 (2016).
 34. Editorial. Full spectrum genetics. Nature genetics 44, 1, doi:10.1038/ng.1057 (2011).
 35. Orphanet. In Prevalence, incidence or number of published cases listed by diseases Vol. www.orpha.net (2016).
 36. Yu, H.-W. Survery for rare genetic diseases among Koreans (한국인 유전성댓질환 실태조사). (Korea Centers for Disease 
Control, LifeScience Medical Center, 2006).
 37. Chakravarti, A. Genomic contributions to Mendelian disease. Genome research 21, 643–644, doi:10.1101/gr.123554.111 (2011).
 38. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760, 
doi:10.1093/bioinformatics/btp324 (2009).
 39. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079, doi:10.1093/bioinformatics/btp352 
(2009).
 40. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature 
genetics 43, 491–498, doi:10.1038/ng.806 (2011).
 41. Abyzov, A., Urban, A. E., Snyder, M. & Gerstein, M. CNVnator: an approach to discover, genotype, and characterize typical and 
atypical CNVs from family and population genome sequencing. Genome research 21, 974–984, doi:10.1101/gr.114876.110 (2011).
 42. Li, J. et al. CONTRA: copy number analysis for targeted resequencing. Bioinformatics 28, 1307–1313, doi:10.1093/bioinformatics/
bts146 (2012).
 43. Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic acids research 44, D862–868, 
doi:10.1093/nar/gkv1222 (2016).
 44. Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting functional effect of human missense mutations using PolyPhen-2. Current 
protocols in human genetics Chapter 7, Unit7 20, doi:10.1002/0471142905.hg0720s76 (2013).
 45. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nature methods 7, 248–249, doi:10.1038/
nmeth0410-248 (2010).
www.nature.com/scientificreports/
1 0Scientific RePoRTS | 7: 9810  | DOI:10.1038/s41598-017-09247-5
Acknowledgements
We thank Fred Brooks for assisting in editing the manuscript. This research was supported by the INNOPOLIS 
Foundation under grant number A2014DD101 and by the Institute for Information & Communications 
Technology Promotion funded by the Ministry of Science, ICT and Future Planning under grant number B0101-
15-0104 to Syntekabio, Inc.
Author Contributions
Y.C., J.J., and J.S.L. designed the work and wrote the manuscript; C.H.L. and E.G.J. performed NGS experiments; 
and C.H.L., M.H.K., J.H.H., Y.K., B.N.L., B.J.K., J.C.J. and G.Y. analyzed NGS data. J.J. and J.S.L. are guarantors of 
this work and had full access to all data in the study.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-09247-5
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
